Early T-cell precursor (ETP) acute lymphoblastic leukemia
Conditions
Interventions
Experimental group:venetoclax combined with HAG regimen (Venetoclax+HHT+low-dose cytarabin+G-CSF))
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age> 14 years old; 2. Cell morphology and immunophenotype are consistent with ETP-ALL diagnosis; 3. The ECOG score is 0-2 points during screening; 4. Expected survival = 2 months; 5. There is no abnormal function of the organs that limit the use of the scheme during the screening period; 6. Understand the research and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with oral medication difficulties or malabsorption syndrome; 2. Diseases with abnormal function of heart, lung, liver, kidney and other organs that may limit patients' participation in this test (including but not limited to serious infection, uncontrollable diabetes, severe cardiac insufficiency or angina, active tuberculosis, asthma, COPD, bronchiectasis, etc.); 3. Cardiac ultrasound LVEF 1.5 ULN (upper limit of normal); ALT or AST or ALP>5ULN; serum creatinine > 1.5 ULN; 6. known HIV infection; 7. Systemic conditions are not suitable for chemotherapy; 8. Unable to understand or follow the research protocol; 9. Subjects receiving potent or intermediate-potency CYP3A inducers/inhibitors within 7 days prior to initiation of study therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Event free survival; | — |
Countries
China
Contacts
Public ContactJin Jie
the First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed